What did FDA do about tanning bed rules?
FDA withdrew stricter tanning-bed proposals after opposition
Health regulators in the Trump administration backed away from an effort to more heavily regulate indoor tanning after protests from medical groups warning about risks. In parallel, the U.S. Food and Drug Administration ultimately withdrew a proposed rule that would have barred Americans under age 18 from using tanning beds.
The policy shift is notable because proposals to restrict youth tanning are typically driven by evidence that ultraviolet exposure from indoor tanning is linked to skin-cancer risk and that preventing exposure during adolescence can reduce lifelong harm.
In the developments described, the regulatory change happened in two steps:
- Plans to restrict tanning: officials pursued a proposed rule to bar under-18s from using tanning beds.
- Backtracking: the FDA later withdrew that proposed rule; the change was supported by RFK Jr.’s backing in the description provided.
Why it matters
- Access for teens: the withdrawal means the contemplated federal restriction on minors did not move forward.
- Regulatory consistency: reversals like this can affect how quickly states, insurers, schools, and public health campaigns respond.
- Public health messaging: when federal proposals are paused or dropped, education efforts aimed at reducing indoor UV exposure often remain the main tool.
The provided information does not include details about whether alternative measures (for example, targeted warning labels or enforcement changes) were implemented in place of the withdrawn rule. It also doesn’t specify the exact legal or scientific rationale for the withdrawal beyond the described political/medical opposition context.
Overall, the FDA’s withdrawal represents a setback for a commonly advocated youth-protection strategy aimed at lowering skin-cancer risk linked to indoor tanning.